Increased prevalence of lymphoid tissue inducer cells in the cerebrospinal fluid of patients with early multiple sclerosis

Multiple Sclerosis

Volumn 22, Issue 8, 2016, Pages 1013-1020

  Degn, Matilda ^a   Modvig, Signe ^a   Dyring Andersen, Beatrice ^b   Bonefeld, Charlotte M ^b   Frederiksen, Jette L ^a   Geisler, Carsten ^b   Von Essen, Marina R ^b,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Mental Health Center Glostrup   (Denmark)

Author keywords

CSF pleocytosis; Early multiple sclerosis; inflammation; innate lymphoid cells; innate lymphoid tissue inducer cells

Indexed keywords

ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATION; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOID CELL; LYMPHOID TISSUE INDUCER CELL; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PLEOCYTOSIS; PREVALENCE; YOUNG ADULT; ADOLESCENT; CASE CONTROL STUDY; CYTOLOGY; DISEASE EXACERBATION; HELPER CELL; IMMUNOLOGY; IMMUNOPHENOTYPING; INNATE IMMUNITY; LEUKOCYTE COUNT; PROCEDURES; CELL POPULATION; CYTOKINE RELEASE; DISEASE COURSE; LYMPHOID TISSUE; OPTIC NEURITIS;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CEREBROSPINAL FLUID; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNITY, INNATE; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PHENOTYPE; T-LYMPHOCYTES, HELPER-INDUCER; YOUNG ADULT;

CD123 ANTIGEN; CD14 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; GLYCOPROTEIN P 15095; T6 ANTIGEN;

EID: 84978066752     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515609795     Document Type: Article

References (35)

1. Siffrin V, Vogt J, Radbruch H, et al. Multiple sclerosis-candidate mechanisms underlying CNS atrophy. Trends Neurosci 2010; 33: 202-210.
2. Lublin FD, Reingold SC,. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-911.
3. Matusevicius D, Kivisakk P, He B, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999; 5: 101-104.
4. Xu W, Li R, Dai Y, et al. IL-22 secreting CD4+ T cells in the patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2013; 261: 87-91.
5. Carrieri PB, Provitera V, De RT, et al. Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity. Immunopharmacol Immunotoxicol 1998; 20: 373-382.
6. Carlson T, Kroenke M, Rao P, et al. The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J Expl Med 2008; 205: 811-823.
7. Bielekova B, Richert N, Herman ML, et al. Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology 2011; 77: 1877-1886.
8. Ruocco G, Rossi S, Motta C, et al. T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosis. Clin Sci (Lond) 2015; 129: 291-303.
9. Goverman J,. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 2009; 9: 393-407.
10. Walker JA, Barlow JL, McKenzie AN,. Innate lymphoid cells-how did we miss them? Nat Rev Immunol 2013; 13: 75-87.
11. Spits H, Artis D, Colonna M, et al. Innate lymphoid cells-a proposal for uniform nomenclature. Nat Rev Immunol 2013; 13: 145-149.
12. Liang HE, Reinhardt RL, Bando JK, et al. Divergent expression patterns of IL-4 and IL-13 define unique functions in allergic immunity. Nat Immunol 2011; 13: 58-66.
13. Wilhelm C, Hirota K, Stieglitz B, et al. An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol 2011; 12: 1071-1077.
14. Peters A, Pitcher LA, Sullivan JM, et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 2011; 35: 986-996.
15. Haugen M, Frederiksen JL, Degn M,. B cell follicle-like structures in multiple sclerosis-with focus on the role of B cell activating factor. J Neuroimmunol 2014; 273: 1-7.
16. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
17. Freedman MS, Thompson EJ, Deisenhammer F, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 2005; 62: 865-870.
18. Abraira V, Alvarez-Cermeno JC, Arroyo R, et al. Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice. J Immunol Meth 2011; 371: 170-173.
19. Gout O, Bouchareine A, Moulignier A, et al. Prognostic value of cerebrospinal fluid analysis at the time of a first demyelinating event. Mult Scler 2011; 17: 164-172.
20. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
21. Spits H, Di Santo JP,. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011; 12: 21-27.
22. Strowig T, Brilot F, Munz C,. Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity. J Immunol 2008; 180: 7785-7791.
23. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103: 5941-5946.
24. Spits H, Cupedo T,. Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu Rev Immunol 2012; 30: 647-75.
25. Hwang YY, McKenzie AN,. Innate lymphoid cells in immunity and disease. Adv Exp Med Biol 2013; 785: 9-26.
26. Buonocore S, Ahern PP, Uhlig HH, et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 2010; 464: 1371-1375.
27. Chang YJ, Kim HY, Albacker LA, et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol 2011; 12: 631-638.
28. Lin YC, Winokur P, Blake A, et al. Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis. Ann Clin Transl Neurol 2015; 2: 445-455.
29. Khademi M, Kockum I, Andersson ML, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler 2011; 17: 335-343.
30. van de Pavert SA, Olivier BJ, Goverse G, et al. Chemokine CXCL13 is essential for lymph node initiation and is induced by retinoic acid and neuronal stimulation. Nat Immunol 2009; 10: 1193-1199.
31. Modvig S, Degn M, Roed H, et al. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult Scler. 2015; 21: 1761-1770.
32. Elkins J, Sheridan J, Amaravadi L, et al. CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm 2015; 2: e65.
33. Perry JS, Han S, Xu Q, et al. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med 2012; 4: 145ra106.
34. Aloisi F, Pujol-Borrell R,. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006; 6: 205-217.
35. Sellebjerg F, Bornsen L, Khademi M, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009; 73: 2003-2010.